Online healthcare provider Hims Hers Health ($HIMS) asked a federal judge to dismiss a lawsuit that accuses the company of ...
Hims argued that the agency ignored the company’s disclosures and misapplied federal law on subscriptions and privacy.
The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.
Stocktwits on MSN
HIMS stock gains as company enters German men’s weight market as investors watch US peptide compounding policy
The new launch builds on the company’s earlier efforts at expanding in Europe, including the acquisition of UK-based health ...
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new ...
Suppose improving growth and profitability allow investors to value the company at 2.5x expected 2027 sales. Applying that multiple to the $3.99 billion revenue estimate produces a market ...
The plan would apparently temporarily allow specialty pharmacies to compound certain unapproved peptides, including BPC-157.
Hims & Hers Health has been a dramatic ride for shareholders over the past few years, yet recent share price weakness now has ...
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...
Hims & Hers stock jumps as HHS reviews policy letting compounding pharmacies make peptides like BPC-157. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results